Pipeline

We are developing a differentiated portfolio of RNA-based immunotherapies to transform outcomes for patients with cancer.
Oncorus Pipeline.
Therapy
Indications
Development Stage
5 stages: Research, IND-enabling, Phase 1, Phase 2, Phase 3
Commercial Rights
ONCR-021
  • NSCLC
  • HCC
  • ccRCC
  • Melanoma
  • ATC
IND-Enabling
Oncorus
ONCR-788
  • SCLC
  • Prostate and other neuroendocrine tumors
Research
Oncorus
ONCR-719
  • Glioblastoma multiforme
  • Other CNS tumors
Research
Oncorus
ccRCC = clear cell renal cell carcinoma; CNS = central nervous system; GBM = glioblastoma multiforme; HCC = hepatocellular carcinoma; IND = investigational new drug; NSCLC = non-small cell lung cancer; SCLC = small cell lung cancer; vRNA = viral RNA; ATC = anaplastic thyroid cancer If you are interested in partnering with Oncorus, please contact us.